Accéder au contenu
Merck

11086090001

Roche

Calpain Inhibitor I

N-Acetyl-Leu-Leu-norleucinal, synthetic

Synonyme(s) :

Calpain Inhibitor I, n-acetyl-leu-leu-norleucinal, ALLN, Ac-LLnL-CHO, MG-101, N-Acetyl-L-leucyl-L-leucyl-L-norleucinal, N-Acetyl-Leu-Leu-Norleu-al

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement


A propos de cet article

Formule empirique (notation de Hill) :
C20H37N3O4
Numéro CAS:
Poids moléculaire :
383.53
PubChem Substance ID:
UNSPSC Code:
12352204
Beilstein/REAXYS Number:
7656053
MDL number:
NACRES:
NA.54
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

SMILES string

[H]C(=O)[C@H](CCCC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O

InChI

1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1

InChI key

FMYKJLXRRQTBOR-BZSNNMDCSA-N

assay

98% (chromatographically homogeneous)

form

powder

mol wt

Mr = 383.5

packaging

pkg of 25 mg

manufacturer/tradename

Roche

mp

182 °C

solubility

DMF: 10 mg/mL, ethanol: 10 mg/mL, methanol: 10 mg/mL

storage temp.

2-8°C

Quality Level

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

General description

Calpain Inhibitor I is a strong, competitive inhibitor of the Ca2+-dependent neutral cysteine proteases calpain I and calpain II.

Application

Calpain inhibitor I inhibits calpain, which activates myosin light chain kinase and protein kinase C by partial proteolysis. The inhibitor should be membrane permeable due to low molecular weight and lack of charged residues.
Calpain Inhibitor I is used for western blotting methods.

Biochem/physiol Actions

Calpain Inhibitor I is a strong, competitive inhibitor of the Ca2+-dependent neutral cysteine proteases calpain I (requiring 2–75 μM Ca2+ for activation) and calpain II (requiring 200–800 μM) with a Ki-value between 0.12 μM and 0.23 μM. Calpain II is inhibited to a lesser extent than calpain I. Calpain Inhibitor I is also a strong inhibitor of papain and cathepsin B and L. It shows only weak inhibition of cathepsin H and α-chymotrypsin and does not inhibit trypsin. ID50 for 0.02 U platelet calpain is 0.05 μM.

Preparation Note

Working concentration: 0.1 - 10 μM
The suggested starting concentration is 17 μg/ml. This is the concentration at which half maximal inhibition of calpain I is observed.
Working solution: Recommended solvent is DMF, ethanol, or methanol up to 10 mg/ml.
Storage conditions (working solution): -15 to -25 °C
Solutions in DMF, methanol, ethanol are stable for 4 weeks at -15 to -25 °C.
C20H37N3O4
Soluble in DMF, ethanol, or methanol to 10 mg/ml. For a stock solution, Roche recommends dissolving 1 mg of the inhibitor in 100 μl DMF, methanol, or ethanol. Before use, dilute with water or phosphate buffer (0.1 M, pH 7.5) to desired concentration. Solutions in DMF, ethanol, or methanol are stable for 2 to 3 days at 2 to 8 °C, and approximately 4 weeks at -15 to -25 °C. For best results, prepare solutions fresh before use.

Analysis Note

Purity: 98% (from C); chromatographically homogeneous

Other Notes

For life science research only. Not for use in diagnostic procedures.

Classe de stockage

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Erdinç Dursun et al.
Journal of Alzheimer's disease : JAD, 23(2), 207-219 (2010-10-23)
Amyloid-β (Aβ) is the core component of amyloid plaques of Alzheimer's disease (AD). The effects of Aβ include damage to neuronal plasma membrane, disruption of Ca(2+) homeostasis, and alterations of neurotrophic factor levels. The aim of this study was to
Sami Salmikangas et al.
Microorganisms, 8(12) (2020-12-10)
The current methods to study the distribution and dynamics of viral RNA molecules inside infected cells are not ideal, as electron microscopy and immunohistochemistry can only detect mature virions, and quantitative real-time PCR does not reveal localized distribution of RNAs.
Takahisa Hirokawa et al.
International journal of molecular sciences, 22(15) (2021-08-08)
Tauopathies are neurodegenerative diseases characterized by abnormal metabolism of misfolded tau proteins and are progressive. Pathological phosphorylation of tau occurs in the retinal ganglion cells (RGCs) after optic nerve injuries. Cyclin-dependent kinase-5 (Cdk5) causes hyperphosphorylation of tau. To determine the
Duygu Gezen-Ak et al.
PloS one, 6(3), e17553-e17553 (2011-03-17)
Recent studies have suggested that vitamin D can act on cells in the nervous system. Associations between polymorphisms in the vitamin D receptor (VDR), age-dependent cognitive decline, and insufficient serum 25 hydroxyvitamin D(3) levels in Alzheimer's patients and elderly people

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique